Bedrich L. Eckhardt

Bedrich L. Eckhardt

Auto-generated profile, based on publicly available information

Bedrich L. Eckhardt

Olivia Newton-John Cancer Research Institute, Heidelberg, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
BEBedrich L. Eckhardt
Bedrich L. Eckhardt
YCYuan Cao
Yuan Cao
ARAndrew D. Redfern
Andrew D. Redfern
LCLap Hing Chi
Lap Hing Chi
ABAllan D. Burrows
Allan D. Burrows
RARobin Anderson
Robin Anderson
Metastasis is the major cause of death in patients with cancer; with no therapeutic cure, treatments remain largely palliative. As such, new targets and therapeutic strategies are urgently required. Here, we show that bone morphogenetic protein-4 (BMP4) blocks metastasis in animal models of breast cancer and predicts improved survival in patients. In preclinical models of spontaneous metastasis, BMP4 acted as an autocrine mediator to modulate a range of known metastasis-regulating genes, including Smad7, via activation of canonical BMP-SMAD signaling. Restored BMP4 expression or therapeutically administered BMP4 protein, blocked metastasis and increased survival by sensitizing cancer cells to anoikis, thereby reducing the number of circulating tumor cells. Gene silencing of Bmp4 or its downstream mediator Smad7, reversed this phenotype. Administration of recombinant BMP4 markedly reduced spontaneous metastasis to lung and bone. Elevated levels of BMP4 and SMAD7 were prognostic for improved recurrence-free survival and overall survival in patients with breast cancer, indicating the importance of canonical BMP4 signaling in the suppression of metastasis and highlighting new avenues for therapy against metastatic disease. Significance: Targeting the BMP4–SMAD7 signaling axis presents a novel therapeutic strategy to combat metastatic breast cancer, a disease that has had no reduction in patient mortality over 20 years.

30 April 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JFJose Rodrigo Espinosa Fernandez
Jose Rodrigo Espinosa Fernandez
BEBedrich L Eckhardt
Bedrich L Eckhardt
JLJangsoon Lee
Jangsoon Lee
BLBora Lim
Bora Lim
TPTroy Pearson
Troy Pearson
Naoto T UenoNaoto T Ueno
Naoto T Ueno
The original algorithm that classified triple-negative breast cancer (TNBC) into six subtypes has recently been revised. The revised algorithm (TNBCtype-IM) classifies TNBC into five subtypes and a modifier based on immunological (IM) signatures. The molecular signature may differ between cancer cells in vitro and their respective tumor xenografts. We identified cell lines with concordant molecular subtypes regardless of classification algorithm or analysis of cells in vitro or in vivo, to establish a panel of clinically relevant molecularly stable TNBC models for translational research. Gene expression data were used to classify TNBC cell lines using the original and the revised algorithms. Tumor xenografts were established from 17 cell lines and subjected to gene expression profiling with the original 2188-gene algorithm TNBCtype and the revised 101-gene algorithm TNBCtype-IM. A total of six cell lines (SUM149PT (BL2), HCC1806 (BL2), SUM149PT (BL2), BT549 (M), MDA-MB-453 (LAR), and HCC2157 (BL1)) maintained their subtype classification between in vitro and tumor xenograft analyses across both algorithms. For TNBC molecular classification–guided translational research, we recommend using these TNBC cell lines with stable molecular subtypes.

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
BEBedrich Eckhardt
Bedrich Eckhardt
KMKellie Mouchemore
Kellie Mouchemore
YLYang Liao
Yang Liao
WSWei Shi
Wei Shi
FMFrancesca Mercuri
Francesca Mercuri
AGAnna Galkin
Anna Galkin
Background Treatment approaches that engage both the innate and adaptive immune response have the potential to transform anti-cancer therapy, especially in settings of checkpoint inhibitor insensitivity. Toll-like receptors (TLRs) mediate the initial cellular response to external pathogens or endogenous alarmins, activating downstream pro-inflammatory cascades associated with innate cell activation and recruitment. AXA-042 is a novel synthetic TLR2/6 agonist designed for systemic delivery to re-engage the innate immune response to help overcome tumor immune escape. Once-a-week treatment with AXA-042 led to 87% growth inhibition of syngeneic EMT6 tumors. Single cell sequencing analysis was completed to characterize the immediate impact of systemic TLR2/6 activation on the tumor microenvironment. Methods Female Balb/c mice bearing orthotopic EMT6.5 mammary tumors received a single intravenous treatment of saline or AXA-042 (10 μg/mouse). Equal numbers of viable cells were recovered by flow cytometry from collagenase-digested tumors (n=3/group) 24 hours after treatment and pooled prior to loading onto a Chromium Single Cell Chip. 10x Genomics single-cell transcriptome libraries were prepared from each sample and sequenced with Illumina NextSeq 550 sequencing platform. Cell type annotation based on the ImmGen database was determined using the SingleR package. Differential gene expression analyses were completed to identify AXA-042 responsive gene signatures in cell subsets that included at least 10 cells. The identified genes were required to be expressed in at least 3 cells. Results AXA-042 treatment decreased the total number of tumor-associated macrophages, monocytes, fibroblasts, endothelial, epithelial and stromal cells within 24 hours of treatment. A parallel increase in neutrophils, B cells, NKT and activated CD4 and CD8 T cells was observed. Re-clustering of myeloid populations revealed AXA-042-induced shifts in the macrophage, monocyte and neutrophil clusters. Differential expression analysis within the TLR2 positive myeloid cells demonstrated AXA-042-mediated engagement of pathways associated with antigen processing and presentation, Fc receptor signaling and immune hypersensitivity in monocytes; granulocyte chemotaxis, lipid metabolism and iron sequestration in neutrophils; and cellular response to bacterial lipopeptide, stress response to metal ions and arginine metabolism in macrophages Conclusions Systemic AXA-042 treatment led to a reorganization of the tumor microenvironment within 24 hours of treatment. AXA-042 altered the myeloid cell subset profiles, promoted the influx of activated T cells and reduced tumor cell viability. AXA-042 has completed GLP toxicology studies and is currently undergoing evaluation in a Phase 1 clinical trial (ACTRN12622000993796) in advanced solid tumors. Trial Registration ACTRN12622000993796 Ethics Approval The study was approved by the Austin Health Animal Ethics Committee, approval number 05640.